COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,893 Articles (22,568 medRxiv, 8,325 bioRxiv)

Most recent first Previous |  Page 131: Articles 1301-1310  | Next

Adapting COVID-19 research infrastructure to capture influenza and RSV alongside SARS-CoV-2 in UK healthcare workers winter 2022/23: Evaluation of the SIREN Winter Pressures pilot study
Munro, K., Russell, S., Foulkes, S., Broad, J., Sparkes, D., Atti, A., Islam, J., Hopkins, S., Hall, V., SIREN study group
10.1101/2024.09.08.24313279 — Posted: 2024-09-09
Efficacy of Molnupiravir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).
Gentile, I., Scotto, R., Scirocco, M. M., Di Brizzi, F., Cuccurullo, F., Silvitelli, M., Ametrano, L., Alfe', F. A., Pietroluongo, D., Irace, I., Chiariello, M., De Felice, N., Severino, S., Viceconte, G., Schiano Moriello, N., Maraolo, A. E., Buonomo, A. R., Giaccone, A., Federico II COVID Team
10.1101/2024.09.09.24313305 — Posted: 2024-09-09
Discovery of novel quinoline papain-like protease inhibitors for COVID-19 through topology constrained molecular generative model
Shang, J., Ran, T., Lu, Y., Yang, Q., Zhang, G., Zhou, P., Li, W., Xu, M., Dai, M., Zhong, J., Chen, H., He, P., Zhou, A., Xue, B., Chen, J., Zhang, J., Wu, K., Wu, X., Tang, M., Chen, X., Chen, H.
10.1101/2024.09.07.611841 — Posted: 2024-09-09
A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and combines a direct antiviral effect with subtle boosting of interferon
Van Loy, B., Pujol, E., Kamata, K., Lee, X. Y., Bakirtzoglou, N., Van Berwaer, R., Vandeput, J., Persoons, L., De Wijngaert, B., Goovaerts, Q., Noppen, S., Ahmadzadeh, K., Martin-Lopez, J., Escriche, C., Vanmechelen, B., Krasniqi, B., Singh, A. K., Maes, P., Matthys, P., Dehaen, W., Rozenski, J., Das, K., Voet, A., Vazquez, S., Naesens, L. M., Stevaert, A.
10.1101/2024.09.09.611961 — Posted: 2024-09-09
Forecasting COVID-19, Influenza and RSV hospitalisations over winter 2023/24 in England
Mellor, J., Tang, M. L., Jones, O., Infectious Disease Modelling Team, , Ward, T., Riley, S., Deeny, S. R.
10.1101/2024.09.07.24313175 — Posted: 2024-09-08
Correlates of COVID-19 conspiracy theory beliefs in Japan: A nationally-representative cross-sectional survey
Sato, Y., Kawachi, I., Saijo, Y., Yoshioka, E., Osaka, K., Tabuchi, T.
10.1101/2024.09.06.24313228 — Posted: 2024-09-07
Impact of vaccination on SARS-CoV-2 transmission in the UK: a modelling study
Derqui, N., Mishra, S., Hinsley, W. R., Bhatt, S., Laydon, D. J.
10.1101/2024.09.06.24313210 — Posted: 2024-09-07
Evaluating the Risk of Cardiovascular Adverse Events and Appendicitis After COVID-19 Diagnosis in Adults in the United States: Implications of the Start of Follow-Up
Layton, J. B., Lindaas, A., Muthuri, S. G., Lloyd, P. C., Richey, M. M., Gruber, J. F., Lyu, H., McKillop, M. M., Kowarski, L. S., Bui, C., Fisher, S. S., Clarke, T. C., Cheng, A. S., Wan, Z., Duenas, P. F., Chen, Y., Burrell, T., Sheng, M., Shoaibi, A., Chillarige, Y., Beers, J., Anthony, M. S., Forshee, R. A., Anderson, S. A.
10.1101/2024.09.05.24313134 — Posted: 2024-09-06
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Horby, P. W., Emberson, J. R., Thwaites, L., Campbell, M., Peto, L., Pessoa-Amorim, G., Staplin, N., Hamers, R. L., Amuasi, J., Nel, J., Kestelyn, E., Phong, N. T., Shrestha, A., Nasronudin, N., Sarkar, R., Thach, P. N., Patel, D., Samardi, U., Stewart, R., Nelwan, E., Rawal, M., Baillie, J. K., Buch, M. H., Day, J. N., Faust, S. N., Jaki, T., Jeffery, K., Juszczak, E., Knight, M., Lim, W. S., Mafham, M., Montgomery, A., Mumford, A., Rowan, K., Basnyat, B., Haynes, R., Landray, M. J.
10.1101/2024.09.04.24312992 — Posted: 2024-09-06
Religion and COVID 19 Pandemic for better or for worse?
Ranasinghe, S. U. U., Ranasinghe, L. I., Pathiraja, I.
10.1101/2024.09.04.24312776 — Posted: 2024-09-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).